Paediatric Formulation: Design and Development
Paediatric Formulation: Design and Development
English[eng]
9783040000000
dasatinib||Duchenne muscular dystrophy||cyclodextrin inclusion complex||phase solubility studies||paediatric age||liquid formulation||tumorspheres||retinoblastoma||topotecan||penetration||confocal microscopy||poorly water soluble drug||solubility enhancement||grinding||spray congealing||neglected tropical diseases||polymorph||Norvir®||ritonavir||poorly soluble compound||pediatric||palatability assessment||bioavailability||flavor profile||Interleukin-1||anakinra||canakinumab||innovative biotechnologies||autoinflammatory disease||Kawasaki disease||systemic juvenile idiopathic arthritis||personalized medicine||child||pediatrics||neonates||formulation||product development||formulation development||oral||parenteral||topical||inhaled||intra nasal||biopharmaceutics||administration||excipient||NICU||device||medication error||dosage form||modified release||drug delivery||paediatric formulation development||paediatric dosage forms||chronic myeloid leukemia||tyrosine kinase inhibitors||pediatric age||imatinib||nilotinb||ponatinib||Orodispersible formulation||pyrazinamide||pediatric drug delivery||tuberculosis||design of experiments||children||edible films||development||design||paediatric||age-related||palatable||taste-masking||acceptable
English[eng]
9783040000000
dasatinib||Duchenne muscular dystrophy||cyclodextrin inclusion complex||phase solubility studies||paediatric age||liquid formulation||tumorspheres||retinoblastoma||topotecan||penetration||confocal microscopy||poorly water soluble drug||solubility enhancement||grinding||spray congealing||neglected tropical diseases||polymorph||Norvir®||ritonavir||poorly soluble compound||pediatric||palatability assessment||bioavailability||flavor profile||Interleukin-1||anakinra||canakinumab||innovative biotechnologies||autoinflammatory disease||Kawasaki disease||systemic juvenile idiopathic arthritis||personalized medicine||child||pediatrics||neonates||formulation||product development||formulation development||oral||parenteral||topical||inhaled||intra nasal||biopharmaceutics||administration||excipient||NICU||device||medication error||dosage form||modified release||drug delivery||paediatric formulation development||paediatric dosage forms||chronic myeloid leukemia||tyrosine kinase inhibitors||pediatric age||imatinib||nilotinb||ponatinib||Orodispersible formulation||pyrazinamide||pediatric drug delivery||tuberculosis||design of experiments||children||edible films||development||design||paediatric||age-related||palatable||taste-masking||acceptable